Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 552 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR EMA Recommends Extension of Indications for Niraparib September 29, 2020 Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... July 9, 2021 Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma October 20, 2023 31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During... October 19, 2020 Load more HOT NEWS Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar Preliminary Evidence of Efficacy of an Upfront ICI-based Therapeutic Strategy in... Techniques for Successful Glucose Daddies and Babies Relationships
